Clene (NASDAQ:CLNN – Get Free Report) and Shineco (NASDAQ:SISI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Institutional and Insider Ownership
23.3% of Clene shares are held by institutional investors. Comparatively, 4.1% of Shineco shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Clene and Shineco”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clene | $200,000.00 | 265.00 | -$26.17 million | ($3.50) | -1.17 |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
Shineco has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Clene and Shineco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clene | -20,063.96% | N/A | -137.04% |
| Shineco | -380.55% | -79.89% | -33.01% |
Volatility and Risk
Clene has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.76, indicating that its share price is 276% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Clene and Shineco, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clene | 1 | 0 | 6 | 0 | 2.71 |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
Clene currently has a consensus target price of $34.00, suggesting a potential upside of 733.33%. Given Clene’s stronger consensus rating and higher possible upside, equities analysts clearly believe Clene is more favorable than Shineco.
Summary
Clene beats Shineco on 9 of the 14 factors compared between the two stocks.
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
